+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Multivalent Oral Rotavirus Vaccine Market - Global Forecast 2026-2032- Product Image
Multivalent Oral Rotavirus Vaccine Market - Global Forecast 2026-2032- Product Image
New

Multivalent Oral Rotavirus Vaccine Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 184 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6123814
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The multivalent oral rotavirus vaccine market is undergoing structural transformation as healthcare systems, governments, and manufacturers respond to evolving public health needs, procurement environments, and supply-chain realities. Market players are increasingly required to demonstrate operational flexibility, localized manufacturing capabilities, and evidence-based approaches to ensure sustained vaccine access for global pediatric populations.

Market Snapshot: Multivalent Oral Rotavirus Vaccine Market

The multivalent oral rotavirus vaccine market grew from USD 1.39 billion in 2025 to USD 1.50 billion in 2026. It is expected to continue growing at a CAGR of 7.33%, reaching USD 2.28 billion by 2032.

Scope & Segmentation

  • Valency Approaches: Focused on expanding genotype coverage, these formulations address the diversity of rotavirus strains prevalent across global regions.
  • Target Age Groups: Emphasis on early pediatric dosing windows, integrated with routine immunization schedules to optimize protective outcomes.
  • Distribution Channels: Mix of centralized public procurement and private sector pathways, each imposing unique documentation and supply requirements.
  • End User Types: Includes government immunization programs, hospitals, and pediatric clinics, each with distinct training, reporting, and inventory management needs.
  • Dosage Schedules: Structures aligned with existing well-child visits to maximize series completion and adherence efficiency.
  • Regional Coverage: Americas, Europe, Middle East & Africa, and Asia-Pacific, reflecting varying epidemiological landscapes, regulatory maturity, and policy environments.
  • Technology Focus: Oral vaccine delivery, advanced cold-chain logistics, fill-finish manufacturing localization, and genotype surveillance inform product design and implementation strategies.

Key Takeaways

  • Vaccination strategies increasingly prioritize broad and sustained protection against diverse and evolving rotavirus strains, guided by real-world effectiveness data and ongoing genotype surveillance.
  • Manufacturing is moving closer to target markets, with technology transfer and localized production models aimed at mitigating logistics risks and fostering regional self-sufficiency.
  • Procurement sophistication drives competitive differentiation, with public and private buyers seeking value-added elements such as session-size presentations, packaging that reduces wastage, and enhanced lot-tracking capabilities.
  • Implementation support—spanning provider training, adverse event workflows, and supply-chain enablement—has become a defining factor in supplier selection beyond basic product attributes.
  • Regional variation in access and logistics constraints influences packaging design, documentation standards, and the structuring of supplier partnerships to adapt to local execution needs.
  • Stakeholders are required to address operational friction in cold-chain management, inventory continuity, and integration with other pediatric interventions to ensure reliable and sustained vaccine program coverage.

Tariff Impact on the Multivalent Oral Rotavirus Vaccine Value Chain

Anticipated U.S. tariff actions in 2025 introduce cost pressures and increased lead-time unpredictability for vaccine inputs such as bioprocess components, consumables, and packaging. Suppliers may adjust sourcing strategies, restructure distribution, and seek risk-sharing in tender contracts to respond to these shifts. Public buyers are expected to focus on supply security and cost transparency, making operational resilience and contracting flexibility as critical as per-dose economics in sustaining access.

Methodology & Data Sources

This report uses a triangulated approach, combining structured secondary research to map regulatory and market standards, with primary interviews from manufacturers, distributors, and program leaders. Findings are validated by cross-referencing policies, program practices, and supply realities, ensuring accuracy and actionable insights for decision-makers.

Why This Report Matters

  • Guides senior leaders in evaluating supplier reliability, localization readiness, and risk strategies in a dynamic vaccine market.
  • Enables informed decision-making on procurement, operational planning, and program implementation aligned with evolving global and regional requirements.
  • Delivers insights to support strategic partnership and investment choices across public and private segments of the vaccine value chain.

Conclusion

The multivalent oral rotavirus vaccine market is rapidly adapting to intersecting scientific, operational, and policy demands. Leaders can strengthen program value and supply resilience by combining robust evidence, responsive partnerships, and effective risk management to support sustained pediatric protection.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Multivalent Oral Rotavirus Vaccine Market, by Vaccine Type
8.1. Monovalent
8.2. Pentavalent
9. Multivalent Oral Rotavirus Vaccine Market, by Dosage Form
9.1. Lyophilized Powder
9.2. Liquid Oral Suspension
10. Multivalent Oral Rotavirus Vaccine Market, by Vaccine Platform
10.1. Live Attenuated
10.1.1. Human Neonatal Strain
10.1.2. Human Non-Neonatal Strain
10.1.3. Animal-Human Reassortant
10.2. Inactivated
10.2.1. Whole Virus
10.2.2. Split Or Subunit
10.3. Novel Oral Platforms
10.3.1. Virus Like Particle
10.3.2. Vector Based
10.3.3. RNA Based Oral Delivery
11. Multivalent Oral Rotavirus Vaccine Market, by End User Type
11.1. Public Health Facilities
11.1.1. Public Hospitals
11.1.2. Maternal And Child Health Clinics
11.1.3. Community Health Centers
11.2. Private Healthcare Providers
11.2.1. Private Pediatric Clinics
11.2.2. Private Hospitals
11.2.3. Multi-Specialty Clinics
11.3. Retail And Alternative Settings
11.3.1. Retail Pharmacies And Drugstores
11.3.2. Mobile Or Outreach Clinics
11.3.3. Non-Governmental Health Organizations
12. Multivalent Oral Rotavirus Vaccine Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Multivalent Oral Rotavirus Vaccine Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Multivalent Oral Rotavirus Vaccine Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Multivalent Oral Rotavirus Vaccine Market
16. China Multivalent Oral Rotavirus Vaccine Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. Bharat Biotech International Limited
17.6. Bio Farma
17.7. Biological E. Limited
17.8. Cadila Healthcare Limited
17.9. GlaxoSmithKline plc
17.10. Hilleman Laboratories
17.11. Indian Immunologicals Limited
17.12. Lanzhou Institute of Biological Products Co., Ltd.
17.13. Merck & Co., Inc.
17.14. Panacea Biotec Ltd.
17.15. Pfizer Inc.
17.16. Sanofi S.A.
17.17. Serum Institute of India Pvt. Ltd.
17.18. Shantha Biotechnics
17.19. Sinovac Biotech Ltd.
17.20. Takeda Pharmaceutical Company Limited
17.21. Valneva SE
List of Figures
FIGURE 1. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY MONOVALENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY MONOVALENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY MONOVALENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PENTAVALENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PENTAVALENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PENTAVALENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LYOPHILIZED POWDER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LYOPHILIZED POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIQUID ORAL SUSPENSION, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIQUID ORAL SUSPENSION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIQUID ORAL SUSPENSION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY HUMAN NEONATAL STRAIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY HUMAN NEONATAL STRAIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY HUMAN NEONATAL STRAIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY HUMAN NON-NEONATAL STRAIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY HUMAN NON-NEONATAL STRAIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY HUMAN NON-NEONATAL STRAIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY ANIMAL-HUMAN REASSORTANT, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY ANIMAL-HUMAN REASSORTANT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY ANIMAL-HUMAN REASSORTANT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY WHOLE VIRUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY WHOLE VIRUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY WHOLE VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY SPLIT OR SUBUNIT, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY SPLIT OR SUBUNIT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY SPLIT OR SUBUNIT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VIRUS LIKE PARTICLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VIRUS LIKE PARTICLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VIRUS LIKE PARTICLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VECTOR BASED, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VECTOR BASED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VECTOR BASED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RNA BASED ORAL DELIVERY, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RNA BASED ORAL DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RNA BASED ORAL DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY MATERNAL AND CHILD HEALTH CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY MATERNAL AND CHILD HEALTH CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY MATERNAL AND CHILD HEALTH CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE PEDIATRIC CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE PEDIATRIC CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE PEDIATRIC CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY MULTI-SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY MULTI-SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY MULTI-SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL PHARMACIES AND DRUGSTORES, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL PHARMACIES AND DRUGSTORES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL PHARMACIES AND DRUGSTORES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY MOBILE OR OUTREACH CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY MOBILE OR OUTREACH CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY MOBILE OR OUTREACH CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NON-GOVERNMENTAL HEALTH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NON-GOVERNMENTAL HEALTH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NON-GOVERNMENTAL HEALTH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. AMERICAS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 95. AMERICAS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 96. AMERICAS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 97. AMERICAS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
TABLE 98. AMERICAS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
TABLE 99. AMERICAS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
TABLE 100. AMERICAS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, 2018-2032 (USD MILLION)
TABLE 101. AMERICAS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
TABLE 102. AMERICAS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, 2018-2032 (USD MILLION)
TABLE 103. AMERICAS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
TABLE 104. AMERICAS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, 2018-2032 (USD MILLION)
TABLE 105. NORTH AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. NORTH AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 107. NORTH AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 108. NORTH AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
TABLE 109. NORTH AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
TABLE 110. NORTH AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
TABLE 111. NORTH AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, 2018-2032 (USD MILLION)
TABLE 112. NORTH AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
TABLE 113. NORTH AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, 2018-2032 (USD MILLION)
TABLE 114. NORTH AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, 2018-2032 (USD MILLION)
TABLE 116. LATIN AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. LATIN AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 118. LATIN AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 119. LATIN AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
TABLE 120. LATIN AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
TABLE 121. LATIN AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
TABLE 122. LATIN AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, 2018-2032 (USD MILLION)
TABLE 123. LATIN AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
TABLE 124. LATIN AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
TABLE 126. LATIN AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, 2018-2032 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, 2018-2032 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, 2018-2032 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, 2018-2032 (USD MILLION)
TABLE 138. EUROPE MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 139. EUROPE MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 140. EUROPE MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 141. EUROPE MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
TABLE 142. EUROPE MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
TABLE 143. EUROPE MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
TABLE 144. EUROPE MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, 2018-2032 (USD MILLION)
TABLE 145. EUROPE MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
TABLE 146. EUROPE MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, 2018-2032 (USD MILLION)
TABLE 147. EUROPE MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
TABLE 148. EUROPE MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, 2018-2032 (USD MILLION)
TABLE 149. MIDDLE EAST MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 150. MIDDLE EAST MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 151. MIDDLE EAST MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 152. MIDDLE EAST MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
TABLE 153. MIDDLE EAST MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
TABLE 154. MIDDLE EAST MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
TABLE 155. MIDDLE EAST MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, 2018-2032 (USD MILLION)
TABLE 156. MIDDLE EAST MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
TABLE 157. MIDDLE EAST MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, 2018-2032 (USD MILLION)
TABLE 158. MIDDLE EAST MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
TABLE 159. MIDDLE EAST MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, 2018-2032 (USD MILLION)
TABLE 160. AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 161. AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 162. AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 163. AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
TABLE 164. AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
TABLE 165. AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
TABLE 166. AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, 2018-2032 (USD MILLION)
TABLE 167. AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
TABLE 168. AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, 2018-2032 (USD MILLION)
TABLE 169. AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
TABLE 170. AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, 2018-2032 (USD MILLION)
TABLE 171. ASIA-PACIFIC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 172. ASIA-PACIFIC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 173. ASIA-PACIFIC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 174. ASIA-PACIFIC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
TABLE 175. ASIA-PACIFIC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
TABLE 176. ASIA-PACIFIC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
TABLE 177. ASIA-PACIFIC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, 2018-2032 (USD MILLION)
TABLE 178. ASIA-PACIFIC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
TABLE 179. ASIA-PACIFIC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, 2018-2032 (USD MILLION)
TABLE 180. ASIA-PACIFIC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
TABLE 181. ASIA-PACIFIC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, 2018-2032 (USD MILLION)
TABLE 182. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 183. ASEAN MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 184. ASEAN MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 185. ASEAN MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 186. ASEAN MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
TABLE 187. ASEAN MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
TABLE 188. ASEAN MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
TABLE 189. ASEAN MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, 2018-2032 (USD MILLION)
TABLE 190. ASEAN MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
TABLE 191. ASEAN MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, 2018-2032 (USD MILLION)
TABLE 192. ASEAN MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
TABLE 193. ASEAN MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, 2018-2032 (USD MILLION)
TABLE 194. GCC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 195. GCC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 196. GCC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 197. GCC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
TABLE 198. GCC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
TABLE 199. GCC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
TABLE 200. GCC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, 2018-2032 (USD MILLION)
TABLE 201. GCC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
TABLE 202. GCC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, 2018-2032 (USD MILLION)
TABLE 203. GCC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
TABLE 204. GCC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, 2018-2032 (USD MILLION)
TABLE 205. EUROPEAN UNION MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 206. EUROPEAN UNION MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 207. EUROPEAN UNION MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 208. EUROPEAN UNION MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
TABLE 209. EUROPEAN UNION MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
TABLE 210. EUROPEAN UNION MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
TABLE 211. EUROPEAN UNION MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, 2018-2032 (USD MILLION)
TABLE 212. EUROPEAN UNION MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
TABLE 213. EUROPEAN UNION MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, 2018-2032 (USD MILLION)
TABLE 214. EUROPEAN UNION MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
TABLE 215. EUROPEAN UNION MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, 2018-2032 (USD MILLION)
TABLE 216. BRICS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 217. BRICS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 218. BRICS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 219. BRICS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
TABLE 220. BRICS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
TABLE 221. BRICS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
TABLE 222. BRICS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, 2018-2032 (USD MILLION)
TABLE 223. BRICS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
TABLE 224. BRICS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, 2018-2032 (USD MILLION)
TABLE 225. BRICS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
TABLE 226. BRICS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, 2018-2032 (USD MILLION)
TABLE 227. G7 MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 228. G7 MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 229. G7 MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 230. G7 MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
TABLE 231. G7 MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
TABLE 232. G7 MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
TABLE 233. G7 MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, 2018-2032 (USD MILLION)
TABLE 234. G7 MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
TABLE 235. G7 MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, 2018-2032 (USD MILLION)
TABLE 236. G7 MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
TABLE 237. G7 MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, 2018-2032 (USD MILLION)
TABLE 238. NATO MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 239. NATO MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 240. NATO MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 241. NATO MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
TABLE 242. NATO MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
TABLE 243. NATO MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
TABLE 244. NATO MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, 2018-2032 (USD MILLION)
TABLE 245. NATO MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
TABLE 246. NATO MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, 2018-2032 (USD MILLION)
TABLE 247. NATO MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
TABLE 248. NATO MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, 2018-2032 (USD MILLION)
TABLE 249. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 250. UNITED STATES MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 251. UNITED STATES MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 252. UNITED STATES MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 253. UNITED STATES MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
TABLE 254. UNITED STATES MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
TABLE 255. UNITED STATES MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
TABLE 256. UNITED STATES MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, 2018-2032 (USD MILLION)
TABLE 257. UNITED STATES MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
TABLE 258. UNITED STATES MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, 2018-2032 (USD MILLION)
TABLE 259. UNITED STATES MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
TABLE 260. UNITED STATES MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, 2018-2032 (USD MILLION)
TABLE 261. CHINA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 262. CHINA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 263. CHINA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 264. CHINA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
TABLE 265. CHINA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
TABLE 266. CHINA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
TABLE 267. CHINA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, 2018-2032 (USD MILLION)
TABLE 268. CHINA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
TABLE 269. CHINA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, 2018-2032 (USD MILLION)
TABLE 270. CHINA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
TABLE 271. CHINA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Multivalent Oral Rotavirus Vaccine market report include:
  • Bharat Biotech International Limited
  • Bio Farma
  • Biological E. Limited
  • Cadila Healthcare Limited
  • GlaxoSmithKline plc
  • Hilleman Laboratories
  • Indian Immunologicals Limited
  • Lanzhou Institute of Biological Products Co., Ltd.
  • Merck & Co., Inc.
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd.
  • Shantha Biotechnics
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company Limited
  • Valneva SE

Table Information

Report AttributeDetails
No. of Pages184
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.5 Billion
Forecasted Market Value ( USD ) by 2032 $ 2.28 Billion
Compound Annual Growth Rate7.3%
Regions CoveredGlobal
No. of Companies Mentioned18

Related Topics

Related Reports

Rotavirus Vaccine Market - Global Forecast 2026-2032 - Product Image

Rotavirus Vaccine Market - Global Forecast 2026-2032

  • Report
  • 191 Pages
  • Global
From
Rotavirus Vaccine Market Report 2025 - Product Image

Rotavirus Vaccine Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Rotavirus Vaccines Market - Global Strategic Business Report - Product Image

Rotavirus Vaccines Market - Global Strategic Business Report

  • Report
  • 277 Pages
  • Global
From
Rotavirus Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Rotavirus Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Human Papillomavirus (HPV) Vaccine Market Outlook - Forecast Trends, Market Size, Share and Growth Analysis Report (2025-2034) - Product Image

Human Papillomavirus (HPV) Vaccine Market Outlook - Forecast Trends, Market Size, Share and Growth Analysis Report (2025-2034)

  • Report
  • 400 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.